Thermo Fisher Genexus™ Integrated Sequencer

Overview

The Thermo Fisher Genexus™ Integrated Sequencer is a fully automated, benchtop next-generation sequencing (NGS) platform engineered for clinical and translational laboratories seeking end-to-end automation from nucleic acid input to variant report. Unlike conventional NGS workflows requiring discrete instrumentation for library preparation, templating, sequencing, and bioinformatics analysis, the Genexus system unifies all steps within a single instrument using semiconductor-based ion detection technology. It leverages Ion Torrent chemistry—specifically pH change detection during nucleotide incorporation—to deliver rapid, scalable, and reproducible sequencing data. The platform is purpose-built for targeted DNA, RNA, and circulating tumor DNA (ctDNA) applications, with validated workflows supporting oncology, infectious disease, and inherited disorder testing. Its core architecture eliminates manual handoffs between instruments and software environments, reducing human error, operator dependency, and analytical variability—critical requirements for CLIA-certified and CAP-accredited laboratories operating under GLP/GMP-aligned quality systems.

Key Features

• Fully integrated workflow automation: Performs nucleic acid purification (via optional on-instrument prep modules), library construction (including cDNA synthesis), isothermal template amplification, semiconductor sequencing, primary data analysis, and variant calling—all in one instrument.
• Ion Torrent GX5 four-channel semiconductor chip: Each channel delivers 12–15 million reads; channels operate independently or concurrently, enabling multiplexed assay runs (up to 4 distinct assays per run) with flexible throughput scaling.
• Five-minute total hands-on time: Enabled by pre-filled, barcoded reagent cartridges and RFID-tracked consumables; minimal manual intervention required for setup and loading.
• Real-time visual verification system: Integrated camera and sensor suite confirms correct cartridge placement, detects misaligned or expired reagents, and validates consumable integrity prior to run initiation.
• Modular assay deployment: Supports both Ion AmpliSeq™ and Ion AmpliSeq HD™ panels; new assays are delivered as self-contained software packages without requiring full system software upgrades.
• Dual-version software coexistence: Allows concurrent operation of legacy and newly deployed assays on the same instrument—no need to maintain parallel hardware or software environments.

Sample Compatibility & Compliance

The Genexus Integrated Sequencer accepts purified DNA, RNA, and plasma-derived cfDNA inputs across a broad dynamic range (1–100 ng input). It supports FFPE-derived nucleic acids with optimized fragmentation and repair protocols embedded in its assay-specific workflows. All onboard reagents are CE-IVD marked and FDA-cleared for designated IVD indications. The system complies with ISO 13485:2016 for medical device quality management systems and supports audit-ready electronic records per FDA 21 CFR Part 11 when configured with appropriate IT infrastructure and user access controls. Instrument logs, run metadata, and raw signal files are timestamped, immutable, and exportable for regulatory submission or internal QA review.

Software & Data Management

Genexus Software provides a unified, browser-based interface for run planning, monitoring, and reporting. It integrates assay design files, base-calling algorithms, alignment engines (TMAP), variant callers (Torrent Suite™), and clinical interpretation rules into versioned, containerized application bundles. Each bundle includes embedded QC metrics (e.g., % usable reads, coverage uniformity, strand bias), sample-level confidence scores, and traceable reagent lot tracking. Data exports conform to standard formats (FASTQ, BAM, VCF) and support HL7/FHIR-compliant integration with LIS and EMR systems. Audit trails record all user actions—including parameter edits, report approvals, and software updates—with role-based permissions and multi-factor authentication options available.

Applications

• Oncology: Targeted profiling of somatic variants (SNVs, indels, CNVs, fusions) in solid tumors and hematologic malignancies using clinically validated AmpliSeq for Oncology panels.
• Infectious Disease: Rapid pathogen identification and resistance marker detection in respiratory, blood, and CSF samples.
• Hereditary Disorders: Comprehensive germline variant detection in genes associated with cardiomyopathy, epilepsy, and metabolic conditions.
• Research Use Only (RUO): Flexible assay development via custom AmpliSeq panel design and optimization tools.
• Translational Biomarker Discovery: High-reproducibility, low-input RNA-seq for gene expression quantification and fusion detection.

FAQ

What sample types are supported on the Genexus Integrated Sequencer?
Purified genomic DNA, total RNA, and plasma-isolated cfDNA—compatible with FFPE-derived inputs when used with recommended extraction and QC protocols.
Does the system require external bioinformatics infrastructure?
No. Primary analysis (base calling, alignment, variant calling) is performed onboard; secondary analysis and clinical interpretation may be extended to local servers or cloud platforms via standardized API endpoints.
How is assay validation handled during software updates?
Each assay package undergoes independent analytical and clinical validation prior to release; software updates do not invalidate previously cleared assays due to version isolation and backward-compatible metadata handling.
Can multiple users access the system simultaneously?
Yes. Genexus Software supports concurrent login sessions with granular permission sets (e.g., run operator, analyst, administrator) and session timeout policies aligned with institutional security policies.
Is remote monitoring and troubleshooting supported?
Yes. Secure remote diagnostics and log retrieval are enabled via encrypted TLS connections; Thermo Fisher Technical Support can initiate remote assistance with user consent and session logging.